Amyloid diseases of the heart: assessment, diagnosis, and referral

SW Dubrey, PN Hawkins, RH Falk - Heart, 2011 - heart.bmj.com
The amyloidoses are a group of diseases in which amyloid, a proteinaceous substance,
deposits in one or more organs. As many as 23 different precursor proteins to the formation …

Amyloid heart disease

RH Falk, SW Dubrey - Amyloidosis: Diagnosis and treatment, 2010 - Springer
Cardiac involvement in patients with amyloidosis is common. It produces significant clinical
symptoms in about 40% of patients with AL amyloidosis. A significant proportion of patients …

High output heart failure

PA Mehta, SW Dubrey - QJM: An International Journal of …, 2009 - academic.oup.com
The symptoms and signs of heart failure can occur in the setting of an increased cardiac
output and has been termed 'high output heart failure'. An elevated cardiac output with …

The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement.

SW Dubrey, K Cha, J Anderson… - QJM: monthly journal …, 1998 - academic.oup.com
We reviewed clinical presentation, investigations, therapy, prognosis and outcome of 232
patients with primary (AL) cardiac amyloidosis. There were 142 men and 90 women. Median …

Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients

…, V Sanchorawala, J Reisinger, S Dubrey… - Blood, The Journal …, 1998 - ashpublications.org
AL (amyloid light-chain) amyloidosis is an uncommon plasma cell disorder in which
depositions of amyloid light-chain protein cause progressive organ failure and death in a …

Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes.

SW Dubrey, K Cha, M Skinner, M LaValley, RH Falk - Heart, 1997 - heart.bmj.com
OBJECTIVE: To determine whether patients with myocardial amyloidosis due either to AL
(primary) amyloid or familial amyloid have distinguishing echocardiographic or …

Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients

…, P Bergethon, D Sarnacki, K Finn, S Dubrey… - 1996 - ashpublications.org
The morbidity and lethality of AL amyloidosis is caused by the deposition of lg light chains as
fibrillar amyloid protein in vital organs, disrupting their function, and not by the generally low …

A randomized trial of home telemonitoring in a typical elderly heart failure population in North West London: results of the Home‐HF study

O Dar, J Riley, C Chapman, SW Dubrey… - European journal of …, 2009 - Wiley Online Library
Aims Heart failure chiefly affects the elderly, with frequent emergency admissions.
Telemonitoring can identify worsening heart failure but previous randomized trials have …

Cardiac transplantation for amyloid heart disease: the United Kingdom experience

SW Dubrey, MM Burke, PN Hawkins… - The Journal of heart and …, 2004 - Elsevier
BACKGROUND: Heart transplantation (TX) for cardiac amyloidosis is uncommon because of
concern about progression of amyloid in other organs and the possibility of amyloid …

Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement

J Reisinger, SW Dubrey, M Lavalley, M Skinner… - Journal of the American …, 1997 - jacc.org
Objectives. This study sought to determine the spectrum of electrophysiologic abnormalities
found in patients with cardiac involvement due to AL (primary) amyloidosis and to evaluate …